Health Tech Enterprise to launch Net Zero modelling tool at MEDICA – Med-Tech Innovation

The company is using the platform to exhibit its service offerings, designed to support health technology innovators across the full product development pathway.

From strategically mapping the complex NHS structure and integrating vital clinical feedback, to providing independent assessments of product value propositions and identifying suitable NHS trusts for pilot site opportunities, the company’s services are tailored to enable seamless market entry and expansion.

At this year’s show, the company is launching its HealthTech NETZERO service, to help companies evaluate the carbon impact of their medtech innovations.

With healthcare accounting for 5% of world emissions – and an increasing number of countries pledging to deliver sustainable or Net Zero carbon care by 2050 – there is an ever-growing demand for innovators to show how the use of their technology delivers cost effective and exceptional healthcare, and how it helps meet sustainability targets on the road to Net Zero Carbon Healthcare.

This innovative solution provides an opportunity for innovators to assess and communicate the tangible CO2 emission savings achievable through the adoption of their technology, to support carbon reduction targets. It underscores the role technology plays in driving the healthcare industry toward a sustainable and Net Zero carbon future.

Anne Blackwood, CEO of Health Tech Enterprise, said: “We’re thrilled to be returning to MEDICA in 2023 and looking forward to being part of this global health technology meeting once again. The UK is a fantastic market for healthtech innovators to develop, test and launch their new products and we are looking forward to meeting product developers from across the globe and helping them navigate the UK and EU markets.”

Backed by a network of clinicians, operational specialists, and procurement professionals within the UK’s healthcare system, Health Tech Enterprise leverages insights into the challenges and evolving needs of both national and international healthcare landscapes.

Positioned at the forefront of the UK life sciences ecosystem, the company’s exclusive focus on the medical technology sector equips them with a nuanced understanding of commercial dynamics, enabling them to offer bespoke guidance on efficient product development and effective market access strategies.